DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for mitral valve prolapse — screening already-approved drugs against its 30-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMitral valve prolapse maps to a 30-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mitral valve prolapse is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
carbonyl reductase 1 (CBR1) — CBR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-amino-1-tert-butyl-1h-pyrazolo[3,4-d]pyrimidin-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1WMA · 1.24 Å · ligand 3-(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)PHENOL (AB3). Experimental structure, not a prediction.
What the evidence adds up to
Of 10,818 patients screened in a 2004–2006 prospective study, 238 (2.2%) were diagnosed with mitral valve prolapse. Patients with the classic form had an earlier age at first diagnosis, more prominent symptoms, and more frequent diagnoses of other disorders (atrial septal defect, ventricular septal defect, Marfan syndrome, Ehlers-Danlos syndrome) than those with the non-classic form. However, there were no significant differences between the two groups in major complications such as stroke, death, or submission to surgery. The classic form is more tightly associated with morbid complications, and the authors suggest more frequent follow-up may be useful.
In a surgical series of 68 patients with mitral regurgitation due to leaflet prolapse (mean age 37.8 years, 45 posterior and 23 anterior leaflet prolapse), mitral valve repair was performed through a minimal right vertical infraaxillary thoracotomy. There was no operative mortality or severe morbidity. After operation, echocardiography showed absence or trivial regurgitation in 52 patients and mild regurgitation in 16. During follow-up of 3 months to 8 years, one patient (1.5%) required mitral valve replacement through median sternotomy for recurrent severe regurgitation. The other patients remained in good condition.
In children, mitral valve prolapse is described as pathological sagging of one or both mitral valve leaflets into the left atrium during left ventricular systole. The authors note that in 96–99% of cases, functional disorders and minor anomalies of heart development are not detected during examination, remain undiagnosed, or are found by chance during investigation for another pathology.
What is still missing: prospective trials comparing medical management strategies for asymptomatic prolapse, validated risk stratification tools to identify which patients will progress to severe regurgitation or arrhythmia, and long-term outcome data for the paediatric population, where most cases are discovered incidentally.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Cardiology · 1986 · 8 citations
The mitral valve mechanism with normal and prolapsed leaflets in the light of a dynamic model
AbstractA dynamic model was presented to explain some of the clinical and morphologic findings in primary mitral valve prolapse. In normal cases, the leaflets, chorda tendinae, the annular ring, and the papillary muscles represent a functional entity balanced by the pressure force acting upon the leaflets. When the leaflets are larger, as in primary mitral valve prolapse, a negative interference with this balance is achieved, causing an increased traction on the papillary muscles and a concomitant dilatation of the annular ring.
Surgical Repair of Mitral Valve Prolapse Through a Minimal Right Vertical Infraaxillary Thoracotomy
AbstractBACKGROUND: Minimally invasive mitral valve surgery has been proven a safe and cosmetic alternative to the conventional median sternotomy approach. The aim of this study is to retrospectively evaluate the clinical outcome of mitral valve repair for leaflet prolapse through a minimal right vertical infraaxillary thoracotomy (RVIAT). METHODS: From January 2003 to December 2011, 68 patients with mitral regurgitation (MR) due to leaflet prolapse underwent mitral valve repair through a RVIAT approach. There were 37 males and 31 females. The mean age of the patients was 37.8 ± 10.5 years. Of the 68 patients, 45 had posterior leaflet prolapse and 23 had anterior leaflet prolapse. RESULTS: The mean incision length was 7.3 ± 1.8 cm (range 5.5 to 10.0 cm). Mitral valve repair technique included quadrangular resection with or without sliding repair (40 cases), edge to edge technique (six cases), artificial chordae (18 cases), chordal transfer (four cases), and ring annuloplasty was performed in all 68 patients. There was no severe morbidity and operative mortality. Echocardiography after operation demonstrated absence or trivial mitral regurgitation in 52 patients and mild regurgitation in 16 patients. During the 3 months ≈ 8 years' follow-up period, one patient (1.5%) underwent mitral valve replacement through the median sternotomy due to recurrent severe MR. Other patients were in good condition. CONCLUSION: Surgical repair of mitral valve prolapse can be successfully performed through the RVIAT approach achieving excellent cosmetic and clinical results.
The Anatolian Journal of Cardiology · 2012 · 4 citations
Classic and non-classic forms of mitral valve prolapse
AbstractOBJECTIVE: To investigate the significance of the established distinction between classic and non-classic forms of mitral valve prolapsed (MVP). METHODS: We included in this prospective study all patients examined in our preventive cardiology outpatient clinics during the biannual period October 2004-October 2006. We examined in total 10.818 patients, 238 of whom (2.2%) were diagnosed for MVP. We noted relevant demographic and clinical data (gender, age of diagnosis, symptoms, need for hospitalization) and performed statistical comparisons between patients with the classic and those with the non-classic form. Follow-up controls were performed three years afterwards. RESULTS: Patients with the classic form had an earlier age of first diagnosis, more prominent symptoms, and more frequently diagnosis for other disorders (atrial septal defect, ventricular septal defect, Marfan syndrome, Ehlers-Danlos syndrome) than the rest of the patients; however, there were no significant differences as far as certain major complications (stroke, death, submission to surgery) were concerned. CONCLUSION: The classic form of mitral valve prolapse is more tightly associated with morbid complications, and a more frequent follow-up control in this group of patients may be useful.
Dimensions of Critical Care Nursing · 2007 · 0 citations
An Overview of Mitral Valve Prolapse
AbstractIn Brief Mitral valve prolapse is a commonly diagnosed condition involving the cardiac valves. Although usually a benign disorder, there may be complications that require hospitalization in a critical care unit. This article provides an overview of mitral valve prolapse-pathophysiology, signs and symptoms, medical management, potential complications, and nursing management. Mitral valve prolapse is the most common of the valvular disorders. This article presents an overview of the pathophysiology, signs and symptoms, diagnosis, and management of mitral valve prolapse.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
MITRAL VALVE PROLAPSE IN CHILDREN: CLINICAL, FUNCTIONAL FEATURES OF THE CARDIOVASCULAR SYSTEM
AbstractIn the structure of cardiovascular pathology, functional disorders and conditions associated with minor anomalies of heart development are of great importance. In 96-99% of cases, they are not detected during examination, remain undiagnosed, or are detected by chance during examination for another pathology. Mitral valve prolapse (MVP) is a pathological sagging (bending) of one or both mitral valve leaflets into the left atrium during left ventricular systole.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
